Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer
US9279812B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 12, 2012 |
| Grant date | Mar 8, 2016 |
| Priority date | — |
| Expiry date | Nov 27, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the prognosis, therapeutic stratification and treatment of colorectal cancer. More in particular, the present invention discloses that significantly increased levels of transmembrane type 1 neuregulin-1 in tumor-associated mesenchymal cells present in a sample of a patient indicate that the patient has a worse prognosis when compared to patients having low levels of transmembrane type 1 neuregulin-1 in tumor-associated mesenchymal cells. Moreover, the present invention relates to the usage of transmembrane type 1 neuregulin-1 expression in tumor-associated mesenchymal cells to predict resistance to HER1 inhibitors during colorectal cancer therapy and/or to predict whether a patient would benefit from a therapy based on the prevention of neuregulin-1 and/or HER3 activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.